PE20020588A1 - FORMA CRISTALINA ANHIDRA NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)-BENZO[b]TIOFENO - Google Patents
FORMA CRISTALINA ANHIDRA NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)-BENZO[b]TIOFENOInfo
- Publication number
- PE20020588A1 PE20020588A1 PE2001001040A PE2001001040A PE20020588A1 PE 20020588 A1 PE20020588 A1 PE 20020588A1 PE 2001001040 A PE2001001040 A PE 2001001040A PE 2001001040 A PE2001001040 A PE 2001001040A PE 20020588 A1 PE20020588 A1 PE 20020588A1
- Authority
- PE
- Peru
- Prior art keywords
- metoxyphenyl
- piperidin
- thiophene
- benzo
- phenoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMA CRISTALINA ANHIDRA NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)-BENZO[b]TIOFENO (ARZOXIFENO) F-V QUE TIENE UN MODELO DE DIFRACCION DE RAYOS X QUE COMPRENDE AL MENOS UN DE LOS SIGUIENTES PICOS 7,3 +/- 0,2; 15,5 +/- 0,2; 15,9 +/-0,2; 17,6 +/- 0,2 EN 2 0 CUANDO SE OBTIENEN A PARTIR DE UNA FUENTE DE RADIACION DE COBRE. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN COMPUESTO CRISTALINO, UN VEHICULO Y OPCIONALMENTE UN AGENTE ESTABILIZADOR SELECCIONADO DE METIONINA, ACETILCISTEINA, CISTEINA, ESTROGENO ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION F-V QUE COMPRENDE CRISTALIZAR EL COMPUESTO MENCIONADO EN UN DISOLVENTE DE CRISTALIZACION SELECCIONADO POR METANOL, ETANOL, ISOPROPANOL Y SEGUIDAMENTE SECAR EL SOLIDO RESULTANTE HASTA PESO CONSTANTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24225200P | 2000-10-20 | 2000-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020588A1 true PE20020588A1 (es) | 2002-07-06 |
Family
ID=22914051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001001040A PE20020588A1 (es) | 2000-10-20 | 2001-10-18 | FORMA CRISTALINA ANHIDRA NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)-BENZO[b]TIOFENO |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20040014672A1 (es) |
| EP (1) | EP1328521A2 (es) |
| JP (1) | JP2004512333A (es) |
| KR (1) | KR20030037690A (es) |
| CN (1) | CN1268624C (es) |
| AR (1) | AR035355A1 (es) |
| AU (1) | AU2002214534A1 (es) |
| BR (1) | BR0114792A (es) |
| CA (1) | CA2426007A1 (es) |
| CZ (1) | CZ20031098A3 (es) |
| EA (1) | EA005116B1 (es) |
| EC (1) | ECSP034560A (es) |
| HK (1) | HK1061857A1 (es) |
| HR (1) | HRP20030296A2 (es) |
| HU (1) | HUP0301403A3 (es) |
| IL (1) | IL155487A0 (es) |
| MX (1) | MXPA03003432A (es) |
| MY (1) | MY125009A (es) |
| NO (1) | NO20031753L (es) |
| NZ (1) | NZ525364A (es) |
| PE (1) | PE20020588A1 (es) |
| PL (1) | PL360946A1 (es) |
| SK (1) | SK4902003A3 (es) |
| UA (1) | UA76124C2 (es) |
| WO (1) | WO2002034741A2 (es) |
| ZA (1) | ZA200303061B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2541994A1 (en) * | 2003-10-10 | 2005-05-06 | Arjanne Overeem | Solid-state montelukast |
| JP4922163B2 (ja) * | 2004-07-22 | 2012-04-25 | イーライ リリー アンド カンパニー | （ｓ）−６−（４−（２−（（３−（９ｈ−カルバゾール−４−イルオキシ）−２−ヒドロキシプロピル）アミノ）−２−メチルプロピル）フェノキシ）−３−ピリジンカルボキサミドヘミコハク酸塩の結晶質の不定比水和物 |
| EP2222276A1 (en) * | 2007-12-19 | 2010-09-01 | Spectrum Pharmaceuticals, Inc. | Stable elsamitrucin salt formulations |
| EP2305238B1 (en) | 2009-09-25 | 2011-12-14 | Iasomai aktiebolag | N-acetyl-L-cysteine for the treatment of endometriosis |
| PL236889B1 (pl) * | 2017-10-03 | 2021-02-22 | Univ Warszawski Medyczny | Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3989569B2 (ja) * | 1995-02-28 | 2007-10-10 | イーライ リリー アンド カンパニー | ベンゾチオフェン化合物、中間体、組成物および方法 |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| AU6335600A (en) * | 1999-07-29 | 2001-02-19 | Eli Lilly And Company | A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride |
| EP1204655B1 (en) * | 1999-07-29 | 2003-10-01 | Eli Lilly And Company | A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
-
2001
- 2001-10-18 US US10/399,523 patent/US20040014672A1/en not_active Abandoned
- 2001-10-18 PE PE2001001040A patent/PE20020588A1/es not_active Application Discontinuation
- 2001-10-18 IL IL15548701A patent/IL155487A0/xx unknown
- 2001-10-18 NZ NZ525364A patent/NZ525364A/en unknown
- 2001-10-18 MX MXPA03003432A patent/MXPA03003432A/es not_active Application Discontinuation
- 2001-10-18 CZ CZ20031098A patent/CZ20031098A3/cs unknown
- 2001-10-18 JP JP2002537732A patent/JP2004512333A/ja active Pending
- 2001-10-18 SK SK490-2003A patent/SK4902003A3/sk not_active Application Discontinuation
- 2001-10-18 MY MYPI20014862A patent/MY125009A/en unknown
- 2001-10-18 KR KR10-2003-7005501A patent/KR20030037690A/ko not_active Application Discontinuation
- 2001-10-18 EP EP01983079A patent/EP1328521A2/en not_active Withdrawn
- 2001-10-18 BR BR0114792-7A patent/BR0114792A/pt not_active IP Right Cessation
- 2001-10-18 AU AU2002214534A patent/AU2002214534A1/en not_active Abandoned
- 2001-10-18 EA EA200300491A patent/EA005116B1/ru not_active IP Right Cessation
- 2001-10-18 CN CNB018175813A patent/CN1268624C/zh not_active Expired - Fee Related
- 2001-10-18 PL PL01360946A patent/PL360946A1/xx unknown
- 2001-10-18 UA UA2003043576A patent/UA76124C2/uk unknown
- 2001-10-18 CA CA002426007A patent/CA2426007A1/en not_active Abandoned
- 2001-10-18 WO PCT/US2001/027773 patent/WO2002034741A2/en active IP Right Grant
- 2001-10-18 AR ARP010104895A patent/AR035355A1/es unknown
- 2001-10-18 HU HU0301403A patent/HUP0301403A3/hu unknown
-
2003
- 2003-04-15 HR HR20030296A patent/HRP20030296A2/hr not_active Application Discontinuation
- 2003-04-15 NO NO20031753A patent/NO20031753L/no not_active Application Discontinuation
- 2003-04-16 EC EC2003004560A patent/ECSP034560A/es unknown
- 2003-04-17 ZA ZA200303061A patent/ZA200303061B/en unknown
-
2004
- 2004-07-06 HK HK04104903A patent/HK1061857A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0301403A3 (en) | 2009-05-28 |
| CN1268624C (zh) | 2006-08-09 |
| EA200300491A1 (ru) | 2003-08-28 |
| MXPA03003432A (es) | 2003-08-07 |
| BR0114792A (pt) | 2003-08-12 |
| SK4902003A3 (en) | 2003-10-07 |
| JP2004512333A (ja) | 2004-04-22 |
| CN1469872A (zh) | 2004-01-21 |
| EP1328521A2 (en) | 2003-07-23 |
| ECSP034560A (es) | 2003-06-25 |
| HUP0301403A2 (hu) | 2003-10-28 |
| NO20031753D0 (no) | 2003-04-15 |
| HRP20030296A2 (en) | 2003-06-30 |
| UA76124C2 (en) | 2006-07-17 |
| AR035355A1 (es) | 2004-05-12 |
| HK1061857A1 (en) | 2004-10-08 |
| MY125009A (en) | 2006-07-31 |
| KR20030037690A (ko) | 2003-05-14 |
| NZ525364A (en) | 2005-09-30 |
| CZ20031098A3 (cs) | 2003-08-13 |
| PL360946A1 (en) | 2004-09-20 |
| WO2002034741A3 (en) | 2003-01-03 |
| NO20031753L (no) | 2003-04-15 |
| AU2002214534A1 (en) | 2002-05-06 |
| EA005116B1 (ru) | 2004-10-28 |
| ZA200303061B (en) | 2004-07-19 |
| WO2002034741A2 (en) | 2002-05-02 |
| IL155487A0 (en) | 2003-11-23 |
| US20040014672A1 (en) | 2004-01-22 |
| CA2426007A1 (en) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960010637A (ko) | 신규 의약품 | |
| CA2400422A1 (en) | Lamellar structured cosmetic composition | |
| ES2177022T3 (es) | Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo. | |
| DE69901951T2 (de) | Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie | |
| EP1047406A1 (en) | Autoclavable pharmaceutical compositions containing a chelating agent | |
| AR041679A1 (es) | Compuestos polimorfos de mesilato de imatinib | |
| CO5270007A1 (es) | Composiciones que tienen suministro mejorado de activos | |
| ES2174517T3 (es) | Composiciones cosmeticas con dibenciliden sorbitol y siliconas funcionalizadas. | |
| KR890011837A (ko) | 디데하이드로 비타민 d₃유도체 | |
| HUP0400132A2 (hu) | Azolszármazékokat tartalmazó hűtőanyagok üzemanyagcellás hajtóművekben lévő hűtőrendszerekhez | |
| PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
| PE20020588A1 (es) | FORMA CRISTALINA ANHIDRA NO SOLVATADA DE CLORHIDRATO DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL) ETOXI]FENOXI)-2-(4-METOXIFENIL)-BENZO[b]TIOFENO | |
| GT200200065A (es) | Composicion parenteral reconstituible | |
| NO20000466L (no) | Farmasøytisk preparat for sure, lipofile forbindelser i form av en selvregulerende formulering | |
| ES2174591T3 (es) | Composiciones cosmeticas para las axilas con acetato de alquilo inferior. | |
| EP1250925A3 (en) | Nasal spray containing ondansetron hydrochloride | |
| BR0115952A (pt) | Composição de emulsão para administração terapêutica, método de administração, processo para o preparo de uma formulação contendo derivados de fosfato de agentes de transferência de elétrons | |
| BR9912622A (pt) | ácido r- ou s-lipóico cristalino enanciomericamente puro, processo para a preparação de ácido lipóico cristalino, ácido lipóico, e, uso do mesmo | |
| BR0008516A (pt) | Medicamento contendo um derivado sulfo piranosil acil glicerol | |
| KR960007592A (ko) | 신규한 피롤로카바졸 | |
| IT1139974B (it) | Derivati della s-adenosilmetionina,processo per la preparazione e composizioni terapeutiche che li contengono come principio attivo | |
| ATE302579T1 (de) | Kosmetische zusammensetzungen enthaltend vitamin b3 | |
| BRPI0407652A (pt) | método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição | |
| NZ514073A (en) | Taxane formulations having improved solubility | |
| CO5560531A2 (es) | Producto antitranspirante con dibencilideno sorbitol y elastomero en dimeticona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |